Nasdaq:US$15.01 (+0.18) | HKEX:HK$24.32 (+0.62) | AIM:£2.33 (+0.11)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Jun 2012

ASCO 2012: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors